Latest news with #MultipleMyeloma
Globe and Mail
01-08-2025
- Business
- Globe and Mail
Pfizer's Elranatamab Study: Continued Access for Multiple Myeloma Patients
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer Inc. is conducting an Elranatamab Post Trial Access Study for participants with Multiple Myeloma, officially titled 'ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES'. The study aims to provide continued access to elranatamab for patients who have shown clinical benefit in previous trials. This is significant as it supports ongoing treatment for patients with limited options. The intervention being tested is Elranatamab, a drug designed as a heterodimeric humanized full-length bispecific IgG2 kappa antibody. It targets BCMA on Multiple Myeloma cells and CD3 on T cells, aiming to enhance the immune response against cancer cells. The study is designed as an open-label, single-arm trial with no masking, focusing on treatment. All participants receive Elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination, or commercial availability of the drug in their country. The study began on October 3, 2023, and is currently recruiting. The last update was submitted on July 28, 2025. These dates are crucial for tracking the study's progress and understanding its timeline. This update may positively influence Pfizer's stock performance by demonstrating continued commitment to innovative cancer treatments. It may also impact investor sentiment favorably, especially in the context of competitive advancements in cancer therapies. The study is ongoing, with further details available on the ClinicalTrials portal.
Globe and Mail
25-07-2025
- Business
- Globe and Mail
CAR T-Cell Therapy for Multiple Myeloma Pipeline Experiences Rapid Expansion as Over 5+ Leading Companies Advance Novel Therapies
DelveInsight's, 'CAR T-Cell Therapy for Multiple Myeloma Pipeline Insight, 2025,' report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It covers the CAR T-Cell Therapy for Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy for Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the CAR T-Cell Therapy for Multiple Myeloma Pipeline. Dive into DelveInsight's comprehensive report today! @ CAR T-Cell Therapy for Multiple Myeloma Pipeline Outlook Key Takeaways from the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report In July 2025, Janssen Research & Development LLC announced a study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS). DelveInsight's CAR T-Cell Therapy for Multiple Myeloma pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for CAR T-Cell Therapy for Multiple Myeloma treatment. The leading CAR T-Cell Therapy for Multiple Myeloma Companies such as Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. Promising CART-Cell Therapy for Multiple Myeloma Pipeline Therapies such as Cevostamab, Talquetamab, Bortezomib, Dexamethasone, Lenalidomide, Nivolumab and others. Stay ahead with the most recent pipeline outlook for CAR T-Cell Therapy for Multiple Myeloma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ CAR T-Cell Therapy for Multiple Myeloma Treatment Drugs CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs Profile Novartis drug candidate, PHE 885, is in its phase I trials. The study is to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR). The drug is in the development for the multiple myeloma treatment. JNJ-68284528: Janssen Biotech Janssen's drug JNJ-68284528 is currently being evaluated for the treatment of CAR T-Cell Therapy for Multiple Myeloma. The drug is in pre-registration and from the class CAR-T cell therapies. The drug has been designated with orphan drug status. The CAR T-Cell Therapy for Multiple Myeloma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of CAR T-Cell Therapy for Multiple Myeloma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy for Multiple Myeloma Treatment. CAR T-Cell Therapy for Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. CAR T-Cell Therapy for Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR T-Cell Therapy for Multiple Myeloma market Explore groundbreaking therapies and clinical trials in the CAR T-Cell Therapy for Multiple Myeloma Pipeline. Access DelveInsight's detailed report now! @ New CAR T-Cell Therapy for Multiple Myeloma Drugs CAR T-Cell Therapy for Multiple Myeloma Companies Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Intramuscular Molecule Type CAR T-Cell Therapy for Multiple Myeloma Products have been categorized under various Molecule types such as Small molecules Natural metabolites Monoclonal antibodies Product Type Unveil the future of CAR T-Cell Therapy for Multiple Myeloma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ CAR T-Cell Therapy for Multiple Myeloma Market Drivers and Barriers Scope of the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report Coverage- Global CAR T-Cell Therapy for Multiple Myeloma Companies- Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. CART-Cell Therapy for Multiple Myeloma Pipeline Therapies- Cevostamab, Talquetamab, Bortezomib, Dexamethasone, Lenalidomide, Nivolumab and others. CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on CAR T-Cell Therapy for Multiple Myeloma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ CAR T-Cell Therapy for Multiple Myeloma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary CAR T-Cell Therapy for Multiple Myeloma: Overview Pipeline Therapeutics Therapeutic Assessment CAR T-Cell Therapy for Multiple Myeloma – DelveInsight's Analytical Perspective In-depth Commercial Assessment CAR T-Cell Therapy for Multiple Myeloma Collaboration Deals Early Stage Products (Phase I) PHE 885: Novartis Drug profiles in the detailed report….. Pre-clinical Stage JNJ-68284528: Janssen Biotech Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products Drug profiles in the detailed report….. Inactive Products CAR T-Cell Therapy for Multiple Myeloma Key Companies CAR T-Cell Therapy for Multiple Myeloma Key Products CAR T-Cell Therapy for Multiple Myeloma- Unmet Needs CAR T-Cell Therapy for Multiple Myeloma- Market Drivers and Barriers CAR T-Cell Therapy for Multiple Myeloma- Future Perspectives and Conclusion CAR T-Cell Therapy for Multiple Myeloma Analyst Views CAR T-Cell Therapy for Multiple Myeloma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Health Line
15-07-2025
- Health
- Health Line
Understanding the Stages of Multiple Myeloma
Key takeaways Multiple myeloma is a cancer of the blood that affects plasma cells, and its progression is determined using the Durie-Salmon Staging System or the Revised International Staging System (RISS). The stages of multiple myeloma range from 0 to 3, with higher stages indicating that the cancer has spread and will likely require more intensive treatment. Treatments for multiple myeloma include drug therapies, radiation, and stem cell transplants. Multiple myeloma is a blood cancer that forms in the white blood cells produced by bone marrow. Doctors stage multiple myeloma based on the levels of proteins produced by cancerous cells found throughout the body and other clinical factors affected by cancer. A higher stage means that the cancer has progressed and spread (metastasized). Typically, a higher stage, like stage 3, also causes more symptoms and requires more aggressive treatment. What is multiple myeloma? Multiple myeloma is a type of blood cancer that forms in plasma cells. Plasma cells are a type of white blood cell. Healthy plasma cells are an important part of the immune system and help the body fight infections. When multiple myeloma develops, cancerous plasma cells form. These plasma cells don't help your body fight infection. Over time, these cells multiply and overwhelm your healthy plasma cells. How is multiple myeloma diagnosed and staged? Tests such as bloodwork can help detect multiple myeloma. Blood tests can show the presence of proteins made by cancerous plasma cells. If your doctor suspects multiple myeloma, you might also be asked to do a bone marrow biopsy since plasma cells are produced in your bone marrow. Sometimes, imaging tests such as X-rays or MRIs are done to look for bone damage and other signs of multiple myeloma. Multiple myeloma is staged using the Durie-Salmon Staging System or the Revised International Staging System (RISS). Durie-Salmon Stage System stages of multiple myeloma The Durie-Salmon Stage System assigns stages by looking at: level of kidney function level of blood calcium hemoglobin concentration amount of M protein in blood and urine presence of bone lesions in imaging studies Stage Criteria I • hemoglobin level > 10 g/dL • serum calcium level < 10.5 mg/dL • a normal bone structure or solitary bone plasmacytoma assessed with conventional radiography • low rate of M-component production (IgG level < 5 g/dL; IgA level < 3 g/dL • Bence Jones protein level < 4 g/24 h II Neither stage I nor stage III III One or more of the following: • hemoglobin value < 8.5 mg/dL • serum calcium level > 12.5 mg/dL • advanced lytic bone lesions assessed with conventional radiography • high M-component production rate (IgG value > 7g/dL; IgA value > 5 g/dL; Bence Jones protein > 12 g/24 h) RISS stages of multiple myeloma The RISS assigns stages by looking at: amount of albumin in blood amount of LDH in blood amount of beta-2 microglobulin in blood gene abnormalities of multiple myeloma Below we break down the RISS stages for multiple myeloma and their treatments: Stage 0 multiple myeloma Stage 0 is sometimes called smoldering multiple myeloma or asymptomatic multiple myeloma. At this stage, there are often no symptoms. Clinical criteria for Stage 0 include: blood counts, calcium levels, and kidney function are all normal no bone or organ damage no evidence of amyloid protein buildup serum monoclonal protein greater than or equal to 30 g/L, urinary monoclonal protein greater than or equal to 500 mg per 24 hours, or clonal bone marrow plasma cells 10–60% Stage 0 multiple myeloma treatment Treatment isn't typically needed at this stage. Instead, careful monitoring and regular testing are used to watch for progression. Stage 1 multiple myeloma Multiple myeloma needs to meet certain criteria. This includes: albumin levels greater or equal to 3.5 g/dL serum beta-2 microglobulin less than 3.5 mg/L cytogenetics that are not classed 'high risk' normal LDH levels You might notice symptoms such as bone pain and weakness in your arms and legs at this stage. Stage 1 multiple myeloma treatment Drug therapies are the primary treatment for multiple myeloma. These therapies aim at destroying multiple myeloma cells and include options such as: proteasome inhibitors chemotherapy steroids antibodies immunomodulatory drugs (IMiDs) b-cell maturation antigen (BCMA)-targeted therapies A treatment plan for stage 1 multiple myeloma might include one or a combination of these drug therapies. You might also have treatments such as radiation therapy or a stem cell transplant, depending on your individual treatment plan. Stage 2 multiple myeloma Stage 2 multiple myeloma needs to meet certain criteria. This includes: beta-2 microglobulin between 3.5 mg/L and 5.5 mg/L cytogenetics are either not high risk or have a risk level that is undefined it's not stage 1 or stage 3 By stage 2, symptoms might be more advanced, including loss of appetite or stomach pain. Stage 2 multiple myeloma treatment Treatment options in stage 2 are the same as the treatment options in stage 1. Drug therapies can be used alone or in combination with options such as radiation therapy or a stem cell transplant. In stage 2, higher doses or more potent drugs might be used. Stage 3 multiple myeloma Stage 3 is the most advanced stage of multiple myeloma. To be classed stage 3, multiple myeloma needs to meet these criteria: cytogenetics are considered high risk serum beta-2 microglobulin equal or greater to 5.5 mg/L high levels of LDH Stage 3 multiple myeloma treatment Treatment by stage 3 is more aggressive to slow and stop the cancer from spreading further. Additional treatments with drug therapies are typically still part of treatment plans. A stem cell transplant might also be an option. You and your team can discuss if this is an option for you. RISS stages for multiple myeloma Bottom line Multiple myeloma is a blood cancer that affects plasma cells. Doctors use certain staging systems to discuss how far multiple myeloma has spread. As multiple myeloma advances, stages increase from 1 to 3. Often, later stages require more aggressive treatment.
Hindustan Times
08-06-2025
- Health
- Hindustan Times
India's active Covid-19 cases rise to 6,133, six deaths in last 24 hours
India's active Covid-19 case tally has crossed the 6,000-mark with 378 fresh cases reported in the last 24 hours, Ministry of Health and Family Welfare's (MoHFW) data on Sunday, June 8, showed. India's active Covid-19 case tally stood at 6,133, with Kerala making the biggest contribution in the fresh infections, followed by Gujarat and West Bengal. -Active Covid-19 cases in India: India's active Covid-19 cases rose by 378 since Saturday to stand at 6,133, while 753 people with the infection were cured or discharged in the last 24 hours, the health ministry's data on Sunday showed. -Covid deaths: India also logged six deaths between Saturday and Sunday – two in Karnataka, three in Kerala and one in Tamil Nadu. Details of which are as follows: Karnataka - A 4- year old male with Cor pulmonale, Pulmonary Arterial Hypertension and incidental Covid-19 positive, a 78-year old male with Ischemic Heart Disease, Immune Thrombocytopenic Purpura (and incidental Covid positive. -Kerala Covid deaths: Among the three Covid fatalities in Kerala was a 51-year-old male with SHT, CAD, CKD, a 64-year-old ma;e with T2 DM, CKD, oesophageal adenocarcinoma with metastasis and a 92-year-old male with CAD-Post CABG, CKD Multiple Myeloma, AKI, as per the health ministry. In Tamil Nadu, the patient was a 42-year old male with uncontrolled Diabetes Mellitus, Acute Kidney Disease and seizure disorder. -Kerala, Gujarat log highest cases: Kerala, Gujarat, West Bengal, Rajasthan and Delhi recorded most cases in the last 24 hours. Kerala recorded 144 fresh Covid cases, Gujarat 105, West Bengal 71, Gujarat 24 and Delhi 21. Of the total 6,133 active Covid-19 cases in India, Kerala has the highest share with 1,950 infections. -Cured/discharged: Meanwhile, the number of Covid patients cured or discharged since January 1 this year stood at 6,237 on Sunday. Since January this year, 65 deaths have been reported in the country. There were a total of 257 active patients in the country on May 22.
Yahoo
06-06-2025
- Business
- Yahoo
Heidelberg Pharma to Present at the Life Sciences Virtual Investor Forum June 12th
Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at LADENBURG, Germany, June 06, 2025 (GLOBE NEWSWIRE) -- Heidelberg Pharma AG (XETRA: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that Andreas Pahl, CEO of Heidelberg Pharma, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025. Heidelberg Pharma's lead candidate, HDP-101, a BCMA-targeting ADC with the novel payload Amanitin, is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory Multiple Myeloma. HDP-101 is showing promising results, including a prolonged complete response in a patient who had undergone extensive prior treatment. The patient has received continuous treatment with HDP-101 alone for over 19 months, showing excellent tolerability of the drug. In addition, promising biological activity and objective improvements were observed in several patients, underscoring the potential of HDP-101 as a treatment option for Multiple Myeloma. Dose escalation is continuing, and the study is advancing in cohort 8. Furthermore, the second candidate, HDP-102, a CD-37-targeting ADC with the novel payload Amanitin, has recently entered clinical development and the first patient has been dosed in a Phase I study for the treatment of non-Hodgkin lymphoma (NHL). DATE: June 12th TIME: 10:00 AM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th and 13th This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights Heidelberg Pharma Announced First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025 PR: Heidelberg Pharma Amended Royalty Financing with HealthCare Royalty About Heidelberg Pharma Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells. Heidelberg Pharma uses several compounds and has built up an ADC toolbox that overcomes tumor resistance via numerous pathways and addresses different types of cancer using various antibodies. The goal is to develop targeted and highly effective ADCs for the treatment of a variety of malignant hematologic and solid tumors. Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology. The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at ATAC® is a registered trademark of Heidelberg Pharma Research GmbH. ITAC™, ETAC™ are pending trademark applications of Heidelberg Pharma Research GmbH. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Heidelberg Pharma AG Sylvia Wimmer Director Corporate CommunicationsTel.: +49 89 41 31 38-29E-mail: investors@ Gregor-Mendel-Str. 22, 68526 Ladenburg Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@
